These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 23096231)
1. The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID). Yamazaki T; Kohro T; Chujo M; Ishigaki M; Hashimoto T Hypertens Res; 2013 Feb; 36(2):140-50. PubMed ID: 23096231 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
3. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study). Shiraishi J; Sawada T; Koide M; Yamada H; Matsubara H; Am J Cardiol; 2012 May; 109(9):1308-14. PubMed ID: 22325086 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876 [TBL] [Abstract][Full Text] [Related]
7. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536 [TBL] [Abstract][Full Text] [Related]
8. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006 [TBL] [Abstract][Full Text] [Related]
9. Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study). Macdonald K; Brié H; Vancayzeele S; Lee C; Bowles J; Piotrowski K; Hermans C; Abraham I Arch Cardiovasc Dis; 2013 Mar; 106(3):124-34. PubMed ID: 23582674 [TBL] [Abstract][Full Text] [Related]
10. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820 [TBL] [Abstract][Full Text] [Related]
11. Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Angeli F; Reboldi G; Verdecchia P Hypertens Res; 2013 Feb; 36(2):109-11. PubMed ID: 23154585 [No Abstract] [Full Text] [Related]
12. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Mochizuki S; Dahlöf B; Shimizu M; Ikewaki K; Yoshikawa M; Taniguchi I; Ohta M; Yamada T; Ogawa K; Kanae K; Kawai M; Seki S; Okazaki F; Taniguchi M; Yoshida S; Tajima N; Lancet; 2007 Apr; 369(9571):1431-1439. PubMed ID: 17467513 [TBL] [Abstract][Full Text] [Related]
13. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives]. Weisser B; Vetter H; Mengden T Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025 [TBL] [Abstract][Full Text] [Related]
14. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. Biswas PN; Wilton LV; Shakir SW J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541 [TBL] [Abstract][Full Text] [Related]
15. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Ogihara T; Matsuoka H; Rakugi H Geriatr Gerontol Int; 2011 Oct; 11(4):414-21. PubMed ID: 21410854 [TBL] [Abstract][Full Text] [Related]
16. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study. Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834 [TBL] [Abstract][Full Text] [Related]
17. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE). Saito I; Suzuki H; Kageyama S; Saruta T Clin Exp Hypertens; 2011; 33(2):133-40. PubMed ID: 21269056 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM; Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955 [TBL] [Abstract][Full Text] [Related]
19. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157 [TBL] [Abstract][Full Text] [Related]